Skip to content
lifestyle.hubspotes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
KODIAK SCIENCES INC.
Kodiak Sciences to Present at Three Upcoming Investor Conferences
November 11, 2026
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
October 7, 2026
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
September 28, 2026
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
September 25, 2026
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
August 13, 2026
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
August 10, 2026
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
August 6, 2026